ConductScience.org, home

Comparison · NCT00325403-d810f4a5

UT-15C (Oral Treprostinil) vs Placebo: Clinical Worsening Assessment

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. UT-15C (Oral Treprostinil) vs Placebo: Clinical Worsening Assessment. Trial comparisons, record NCT00325403-d810f4a5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00325403-d810f4a5

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.09930.06110.157wilson
Risk in group 20.1040.05360.192wilson
Risk difference, group 1 minus group 2-0.00456-0.10.0723newcombe hybrid score
Risk ratio, group 1 over group 20.9560.4242.16log
Odds ratio, group 1 over group 20.9510.3852.35log
Number needed to treat, for one fewer participant with the outcome on UT-15C (Oral Treprostinil) than on Placebo219from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1UT-15C (Oral Treprostinil)These subjects were randomly allocated to receive oral treprostinil twice daily and were included in the primary analysis population.15151OG001
Group 2PlaceboThese subjects were randomly allocated to receive placebo twice daily and were included in the primary analysis population.877OG000

Outcome

Type
SECONDARY
Title
Clinical Worsening Assessment
Description
Definition of clinical worsening included patients who met at least one of the following criteria during the 12 weeks of the study:~1. Death (all causes excluding accident)~2. Transplantation or atrial septostomy~3. Clinical deterioration as defined by:~ 1. Hospitalization as a result of PAH, or~ 2. greater than or equal to 20% decrease in 6MWD from Baseline (or too ill to walk) and a decrease in WHO functional class And~ 3. Initiation of new PAH specific therapy (i.e., ERA, PDE5-I, prostacyclin)
Time frame
Baseline and Week 12
Population

Source ClinicalTrials.gov

Trial

Title
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT number
NCT00325403
Phases
PHASE3
Conditions
Pulmonary Hypertension
Interventions
Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
Lead sponsor
United Therapeutics
Results first posted
2013-03-18

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00325403-d810f4a5